239 related articles for article (PubMed ID: 22266923)
1. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
[TBL] [Abstract][Full Text] [Related]
4. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
5. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
6. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R
Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612
[TBL] [Abstract][Full Text] [Related]
7. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
8. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY
Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506
[TBL] [Abstract][Full Text] [Related]
9. Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.
Moreira EL; Rial D; Aguiar AS; Figueiredo CP; Siqueira JM; DalBó S; Horst H; de Oliveira J; Mancini G; dos Santos TS; Villarinho JG; Pinheiro FV; Marino-Neto J; Ferreira J; De Bem AF; Latini A; Pizzolatti MG; Ribeiro-do-Valle RM; Prediger RD
J Neural Transm (Vienna); 2010 Dec; 117(12):1337-51. PubMed ID: 20931248
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.
Franco J; Prediger RD; Pandolfo P; Takahashi RN; Farina M; Dafre AL
Life Sci; 2007 Apr; 80(20):1906-14. PubMed ID: 17382353
[TBL] [Abstract][Full Text] [Related]
11. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.
Monaghan MM; Leddy L; Sung ML; Albinson K; Kubek K; Pangalos MN; Reinhart PH; Zaleska MM; Comery TA
Neurodegener Dis; 2010; 7(1-3):153-9. PubMed ID: 20197696
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
[TBL] [Abstract][Full Text] [Related]
13. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
[TBL] [Abstract][Full Text] [Related]
14. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
15. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
16. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
[TBL] [Abstract][Full Text] [Related]
17. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
Ho SC; Hsu CC; Pawlak CR; Tikhonova MA; Lai TJ; Amstislavskaya TG; Ho YJ
Behav Brain Res; 2014 Jul; 268():177-84. PubMed ID: 24755306
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Barbiero JK; Santiago RM; Persike DS; da Silva Fernandes MJ; Tonin FS; da Cunha C; Lucio Boschen S; Lima MM; Vital MA
Behav Brain Res; 2014 Nov; 274():390-9. PubMed ID: 25127682
[TBL] [Abstract][Full Text] [Related]
19. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
